Leon Moulder, Jr. Acquires 30,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 30,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was bought at an average cost of $16.30 per share, for a total transaction of $489,000.00. Following the acquisition, the chief executive officer directly owned 346,155 shares in the company, valued at $5,642,326.50. This trade represents a 9.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Zenas BioPharma Price Performance

Shares of NASDAQ ZBIO opened at $16.08 on Friday. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. The stock has a fifty day simple moving average of $34.94 and a two-hundred day simple moving average of $24.11. Zenas BioPharma, Inc. has a 1-year low of $5.83 and a 1-year high of $44.60. The firm has a market cap of $863.17 million, a price-to-earnings ratio of -2.27 and a beta of -1.45.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

More Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider purchases — Leon Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (50k @ $16.38, 30k @ $16.30, 20k @ $16.55), spending roughly $1.63M and raising his direct stake to ~366,155 shares (~$6.06M value). Large, repeated CEO buys often signal management confidence and can attract buying interest. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
• Positive Sentiment: Analyst backdrop is constructive — brokerages’ consensus rating sits at “Moderate Buy” with several buy/outperform opinions and elevated average price targets, which can support demand if sentiment persists. Zenas BioPharma Given Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: SEC filings confirm timing and price — multiple Form 4 disclosures document the CEO’s transactions, providing transparency on cost basis and validating the insider activity for investors doing due diligence. SEC filing confirming insider purchases
• Neutral Sentiment: Mixed analyst and price‑target dispersion — while many firms are bullish, some recent revisions (e.g., Morgan Stanley trimming its target) create varied upside expectations that can mute a clear consensus move. MarketBeat ZBIO analyst summary
• Negative Sentiment: Litigation/investigation headline risk — Pomerantz LLP issued an investor alert investigating Zenas, which can trigger short‑term volatility, legal costs, and investor caution until the scope and findings are clarified. Pomerantz investigates Zenas BioPharma

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently added to or reduced their stakes in ZBIO. Federated Hermes Inc. increased its stake in Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after acquiring an additional 703,838 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after purchasing an additional 170,546 shares during the last quarter. Geode Capital Management LLC raised its stake in Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares in the last quarter. Invesco Ltd. purchased a new stake in Zenas BioPharma in the third quarter valued at approximately $3,237,000. Finally, Millennium Management LLC bought a new stake in Zenas BioPharma during the third quarter valued at approximately $1,595,000.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ZBIO shares. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday. Wedbush reissued an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Finally, Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $37.00 to $19.00 in a research note on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.